Member Board of Directors @ The Michael J. Fox Foundation for Parkinson's Research (March 2015 - Present)
Chairman @ Kantum Bio (March 2018 - October 2022)
Member Board of Directors @ (May 2015 - January 2021)
Member Board Of Directors @ (June 2017 - May 2019)
Member Board of Directors @ (February 2003 - March 2018)
Chairman of the Board of Directors @ (April 2014 - March 2016)
Board Member @ Civitas Therapeutics (acquired by Acorda Therapeutics 10/2014) (February 2014 - October 2014)
President, CEO, Founder and Board Member @ Civitas Therapeutics (acquired by Acorda Therapeutics 10/2014) (October 2009 - January 2014)
President and CEO @ BIND Therapeutics (Acquired by Pfizer 6/2016) (January 2007 - September 2009)
President and CEO @ Acceleron Pharma (Acquired by Merck 11/2021) (May 2004 - November 2006)
SVP Operations @ Millennium Pharmaceuticals (Acquired by Takeda 5/2008) (March 2003 - May 2004)
VP Operations @ (June 1999 - March 2003)
Glenn Batchelder Education
Lehigh University
Bachelor's Degree (Chemical Engineering)
1979-1983
Glenn Batchelder Skills
Biopharmaceuticals
Biotechnology
Clinical Development
Clinical Trials
Commercialization
Drug Development
Drug Discovery
FDA
GMP
Life Sciences
Lifesciences
Medical Devices
Oncology
Pharmaceutical Industry
Project Delivery
Regulatory Affairs
Technology Transfer
Marketing
Customer Service
R&d
Strategy
Glenn Batchelder Summary
Glenn Batchelder, based in Cambridge, MA, US, is currently a Venture Partner at Pivotal bioVenture Partners. Glenn Batchelder brings experience from previous roles at Synchronicity Pharma, XyloCor Therapeutics, The Michael J. Fox Foundation for Parkinson's Research and Kantum Bio. Glenn Batchelder holds a 1979 - 1983 Bachelor's Degree in Chemical Engineering @ Lehigh University. With a robust skill set that includes Biopharmaceuticals, Biotechnology, Clinical Development, Clinical Trials, Commercialization and more. Glenn Batchelder has 1 emails and 2 mobile phone numbers on RocketReach.
Looking for a different Glenn Batchelder?
Find contact details for 700 million professionals.